Learn more about GLP-1 drugs and oral health from a past episode of the Dental Sound Bites podcast
This reference genome was used for D50, whereas D14 was solely aligned to the Mus musculus genome
These findings suggest that the neuroprotective mechanisms of these medications may be more selective than previously hypothesized, with particular relevance to Parkinsons disease pathophysiology
Not the right fit for People expecting weight loss results comparable to pharmaceutical GLP-1 drugs
doi: 10.3389/fendo.2024.1528457 Received 14 November 2024 Accepted 30 December 2024 Published 21 January 2025 Volume 15 - 2024 Edited by Claire Joanne Stocker, Aston University, United Kingdom Reviewed by Wael Sidrak, Abou Seifein Diabetes & Endocrine Center, Egypt Frederic Illouz, CHU Angers, France Christine Trapp, Connecticut Childrens Medical Center, United States Updates Copyright 2025 Koceva, Mleku Kozamernik, Jane, Herman, Ferjan and Jensterle
Weight loss itself represents another pathway through which GLP-1 therapy may help rheumatoid arthritis patients